Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • ARTEMIA-FRANCISCANA  (1)
  • Biostabilization  (1)
  • CLINICAL BENEFIT  (1)
  • 1
    Keywords: COMBINATION ; Germany ; TOOL ; GENE ; PROTEIN ; PROTEINS ; METABOLISM ; MOLECULES ; MECHANISM ; mechanisms ; TOLERANCE ; DISCOVERY ; MOLECULE ; WATER ; DAMAGE ; bioinformatics ; MAMMALIAN-CELLS ; STABILITY ; review ; regulation ; HEAT-SHOCK-PROTEIN ; LIFE ; development ; cryopreservation ; BACTERIA ; biotechnology ; STATE ; CHAPERONE ACTIVITY ; WELL ; MILNESIUM-TARDIGRADUM ; RICHTERSIUS-CORONIFER ; ADORYBIOTUS-CORONIFER ; Anhydrobiosis ; ARTEMIA-FRANCISCANA ; Biostabilization ; Cryobanking ; Cryoprotectant ; Cryptobiosis ; DESICCATION TOLERANCE ; FRESH-WATER SPONGE ; SHOCK/ALPHA-CRYSTALLIN PROTEIN ; STRESS-PROTEIN
    Abstract: Certain organisms found across a range of taxa, including bacteria, yeasts, plants and many invertebrates such as nematodes and tardigrades are able to survive almost complete loss of body water. The dry organisms may remain in this state. which is known as anhydrobiosis. for decades without apparent damage. When water again becomes available, they rapidly rehydrate and resume active life. Research in anhydrobiosis has focused mainly on sugar metabolism and stress proteins. Despite the discovery of various molecules which are involved in desiccation and water stress, knowledge of the regulatory network governing the stability of the cellular architecture and the metabolic machinery during dehydration is still fragmentary and not well understood. A combination of transcriptional, proteomic and metabolic approaches with bioinformatics tools can provide a better understanding of gene regulation that underlie the biological functions and physiology related to anhydrobiosis. The development of this concept will raise exciting possibilities and techniques for the preservation and stabilization of biological materials in the dry state. (c) 2009 Elsevier Inc. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 19472511
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: SURVIVAL ; LUNG-CANCER ; DISEASE ; TRIAL ; MUTATIONS ; SQUAMOUS-CELL CARCINOMA ; HEAD ; pancreatic cancer ; NECK-CANCER ; GEMCITABINE ; clinical trial ; CLINICAL BENEFIT ; Advanced disease ; EGFR antibody ; H-R3 ; Nimotuzumab
    Abstract: Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR. Based on phase I data, the recommended dose has been established at 200 mg weekly. This study was aimed at evaluating the safety and efficacy of nimotuzumab monotherapy in patients (pts) with locally advanced or metastatic pancreatic cancer. Methods Pts who failed first line standard chemotherapy for advanced disease and had at least one measurable lesion were eligible for the study. Nimotuzumab was given intravenously at 200 mg once weekly for 6 weeks (wks). Follow up by CT scan was performed after 8 weeks. Pts continued receiving treatment 3-weekly until disease progression or unacceptable toxicity occurred. Endpoints included tumor response (RECIST), progression-free survival (PFS), and safety. Results A total of 56 pts were enrolled for treatment (ECOG status of 1 [n=41] or 0 [n=15]), the majority (47 pts) had metastatic disease. Nearly half of the pts [n=26] received 〉= 2 regimens. Pts evaluable for response: n=36; CR: 0; PR: 0; SD: 6 pts. Median PFS for pts with SD was 19.2 weeks, for all pts 6.7 weeks (95% CI: 6.43-7.14 weeks). PFS after 1 year was 10.3% with a median overall survival of 18.1 weeks. Treatment-related adverse events were generally mild including rash grade 1 in 5 pts. After a single dose of 200 mg, the t(1/2) was calculated to 45 h. Conclusion These data confirm that nimotuzumab is safe and very well tolerated. To improve efficacy, a randomized, placebo-controlled trial with Gem has been initiated
    Type of Publication: Journal article published
    PubMed ID: 21170759
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...